Metastatic Liver Cancer - Pipeline Review, H2 2015


#474844

58pages

Global Markets Direct

$ 2000

In Stock

Metastatic Liver Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Metastatic Liver Cancer - Pipeline Review, H2 2015, provides an overview of the Metastatic Liver Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Liver Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Metastatic Liver Cancer - Overview 7
Pipeline Products for Metastatic Liver Cancer - Comparative Analysis 8
Metastatic Liver Cancer - Therapeutics under Development by Companies 9
Metastatic Liver Cancer - Therapeutics under Investigation by Universities/Institutes 10
Metastatic Liver Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Metastatic Liver Cancer - Products under Development by Companies 13
Metastatic Liver Cancer - Products under Investigation by Universities/Institutes 14
Metastatic Liver Cancer - Companies Involved in Therapeutics Development 15
AB Science SA 15
Arrowhead Research Corporation 16
Mirna Therapeutics, Inc. 17
Transgene Biotek Limited 18
Metastatic Liver Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
masitinib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
MRX-34 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Oncolytic Virus for Liver Metastases and Primary Liver Tumors - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Peptide to Inhibit Hemofiltrate CC Chemokine for Metastatic Liver Cancer - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PSL-001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
TBL-0404 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vaccine for Oncology - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Metastatic Liver Cancer - Recent Pipeline Updates 40
Metastatic Liver Cancer - Dormant Projects 51
Metastatic Liver Cancer - Discontinued Products 52
Metastatic Liver Cancer - Product Development Milestones 53
Featured News & Press Releases 53
Jul 02, 2015: AB Science: the Data and Safety Monitoring Board recommends continuation of three phase 2 studies 53
Jan 14, 2014: Mirna Therapeutics Reports Expansion of Intellectual Property Estate 55
Jul 24, 2013: PreScience Labs Announced that the FDA Accepts IND Application for Novel Oncology Drug 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables
Number of Products under Development for Metastatic Liver Cancer, H2 2015 7
Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Metastatic Liver Cancer - Pipeline by AB Science SA, H2 2015 15
Metastatic Liver Cancer - Pipeline by Arrowhead Research Corporation, H2 2015 16
Metastatic Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2015 17
Metastatic Liver Cancer - Pipeline by Transgene Biotek Limited, H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Metastatic Liver Cancer Therapeutics - Recent Pipeline Updates, H2 2015 40
Metastatic Liver Cancer - Dormant Projects, H2 2015 51
Metastatic Liver Cancer - Discontinued Products, H2 2015 52

List of Figures
Number of Products under Development for Metastatic Liver Cancer, H2 2015 7
Number of Products under Development for Metastatic Liver Cancer - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Targets, H2 2015 20
Number of Products by Stage and Top 10 Targets, H2 2015 20
Number of Products by Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Top 10 Routes of Administration, H2 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 24
Number of Products by Top 10 Molecule Types, H2 2015 26
Number of Products by Stage and Top 10 Molecule Types, H2 2015 26